These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 24510534)
21. C-learning: A new classification framework to estimate optimal dynamic treatment regimes. Zhang B; Zhang M Biometrics; 2018 Sep; 74(3):891-899. PubMed ID: 29228509 [TBL] [Abstract][Full Text] [Related]
22. Doubly robust estimation of optimal dynamic treatment regimes with multicategory treatments and survival outcomes. Zhang Z; Yi D; Fan Y Stat Med; 2022 Oct; 41(24):4903-4923. PubMed ID: 35948279 [TBL] [Abstract][Full Text] [Related]
24. Overview of resistance to systemic therapy in patients with breast cancer. Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229 [TBL] [Abstract][Full Text] [Related]
25. Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy. Pavlík T; Janoušová E; Pospíšil Z; Mužík J; Záčková D; Ráčil Z; Klamová H; Cetkovský P; Trněný M; Mayer J; Dušek L BMC Med Res Methodol; 2011 Oct; 11():140. PubMed ID: 21988861 [TBL] [Abstract][Full Text] [Related]
27. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Pemovska T; Kontro M; Yadav B; Edgren H; Eldfors S; Szwajda A; Almusa H; Bespalov MM; Ellonen P; Elonen E; Gjertsen BT; Karjalainen R; Kulesskiy E; Lagström S; Lehto A; Lepistö M; Lundán T; Majumder MM; Marti JM; Mattila P; Murumägi A; Mustjoki S; Palva A; Parsons A; Pirttinen T; Rämet ME; Suvela M; Turunen L; Västrik I; Wolf M; Knowles J; Aittokallio T; Heckman CA; Porkka K; Kallioniemi O; Wennerberg K Cancer Discov; 2013 Dec; 3(12):1416-29. PubMed ID: 24056683 [TBL] [Abstract][Full Text] [Related]
28. Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer Studies. Kapetanakis V; Prawitz T; Schlichting M; Ishak KJ; Phatak H; Kearney M; Stevens JW; Benedict A; Bharmal M Pharmacoeconomics; 2019 Dec; 37(12):1537-1551. PubMed ID: 31555968 [TBL] [Abstract][Full Text] [Related]
29. Adaptive Treatment Strategies With Survival Outcomes: An Application to the Treatment of Type 2 Diabetes Using a Large Observational Database. Simoneau G; Moodie EEM; Azoulay L; Platt RW Am J Epidemiol; 2020 May; 189(5):461-469. PubMed ID: 31903490 [TBL] [Abstract][Full Text] [Related]
30. Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission. Buyse M; Michiels S; Squifflet P; Lucchesi KJ; Hellstrand K; Brune ML; Castaigne S; Rowe JM Haematologica; 2011 Aug; 96(8):1106-12. PubMed ID: 21546500 [TBL] [Abstract][Full Text] [Related]
31. Novel strategies for relapsed and refractory acute myeloid leukemia. Mato AR; Morgans A; Luger SM Curr Opin Hematol; 2008 Mar; 15(2):108-14. PubMed ID: 18300756 [TBL] [Abstract][Full Text] [Related]
32. Estimation of the optimal regime in treatment of prostate cancer recurrence from observational data using flexible weighting models. Shen J; Wang L; Taylor JMG Biometrics; 2017 Jun; 73(2):635-645. PubMed ID: 27893926 [TBL] [Abstract][Full Text] [Related]
33. A Bayesian Network Meta-Analysis Comparing the Efficacies of Eleven Novel Therapies with the Common Salvage Regimen for Relapsed or Refractory Acute Myeloid Leukemia. Huang J; Gui C; Zhang L; Che F; Wang C Cell Physiol Biochem; 2018; 49(4):1589-1599. PubMed ID: 30223267 [TBL] [Abstract][Full Text] [Related]